"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 3 | 3 | 6 |
| 1998 | 1 | 3 | 4 |
| 1999 | 0 | 2 | 2 |
| 2000 | 3 | 3 | 6 |
| 2001 | 1 | 3 | 4 |
| 2002 | 4 | 2 | 6 |
| 2003 | 3 | 2 | 5 |
| 2004 | 4 | 1 | 5 |
| 2005 | 5 | 3 | 8 |
| 2006 | 5 | 4 | 9 |
| 2007 | 3 | 4 | 7 |
| 2008 | 5 | 3 | 8 |
| 2009 | 4 | 6 | 10 |
| 2010 | 2 | 5 | 7 |
| 2011 | 5 | 5 | 10 |
| 2012 | 3 | 2 | 5 |
| 2013 | 5 | 7 | 12 |
| 2014 | 10 | 7 | 17 |
| 2015 | 11 | 6 | 17 |
| 2016 | 6 | 2 | 8 |
| 2017 | 10 | 4 | 14 |
| 2018 | 4 | 9 | 13 |
| 2019 | 8 | 10 | 18 |
| 2020 | 2 | 5 | 7 |
| 2021 | 1 | 11 | 12 |
| 2022 | 2 | 4 | 6 |
| 2023 | 1 | 4 | 5 |
| 2024 | 5 | 5 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Semaglutide 2.4?mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 2024 Dec; 60(11-12):1525-1533.
-
Updating and calibrating the Real-World Progression In Diabetes (RAPIDS) model in a non-Veterans Affairs population. Diabetes Obes Metab. 2024 Nov; 26(11):5261-5271.
-
Modeling Metformin and Dapagliflozin Pharmacokinetics in Chronic Kidney Disease. AAPS J. 2024 Aug 19; 26(5):94.
-
Expanding Clinical Use of Sodium-glucose Cotransporter-2 Inhibitors? J Cardiothorac Vasc Anesth. 2024 Oct; 38(10):2135-2138.
-
Type 2 Diabetes. Ann Intern Med. 2024 Jun; 177(6):ITC81-ITC96.
-
Food Insecurity and Hypoglycemia among Older Patients with Type 2 Diabetes Treated with Insulin or Sulfonylureas: The Diabetes & Aging Study. J Gen Intern Med. 2024 Oct; 39(13):2400-2406.
-
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy. Ophthalmol Retina. 2024 Oct; 8(10):943-952.
-
Individualizing Care for Older Adults With Diabetes Amid the Revolution in Pharmacotherapy. JAMA Intern Med. 2024 Apr 01; 184(4):435-436.
-
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression. Diabetes Obes Metab. 2024 Jun; 26(6):2209-2228.
-
Willingness to take less medication for type 2 diabetes among older patients: The Diabetes & Aging Study. J Am Geriatr Soc. 2024 Jul; 72(7):1985-1994.